Disruptive Innovation in Rare Disease Markets: the Shifting Paradigm in Hemophilia Management

Regardless of how innovative a new technology may be, all therapeutic approaches face increasing pressure on target product profiles. Determining what benchmarks novel therapies will need to demonstrate in order to prove differentiation and therapeutic value and compete in the changing rare disease landscape should be an early priority for developers. The transformation of the hemophilia market provides an important paradigm for the development of other rare disease treatment landscapes.

Cello Health experts provide in-depth analysis and best practice insights to inform early asset development and commercialization. For more information about Cello Health, visit the website.